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recovery from functional ischemic MR with isolated CABG is unlikely;
in these patients, concomitant mitral valve repair should be considered.
http://dx.doi.org/10.1016/j.ehj.2013.12.063
Serum Osteoprotegerin level and the extent of cardiovascular calciﬁca-
tion in haemodialysis patients
Waleed Ammar a, Mohamed El-Khatib b, Dawlat Belal b, Mahmoud
El-Nokeety b, Amal El-Shehaby c
aCardiology Department, Kasr El-Aini Medical School, Cairo Uni-
versity, Egypt, b Internal Medicine Department, Kasr El-Aini Medical
School, Cairo University, Egypt, cBiochemistry Department, Kasr El-
Aini Medical School, Cairo University, Egypt.
Background: Cardiovascular disease is the leading cause of death in
chronic kidney disease and hemodialysis population. The mechanisms
of vascular damage in this population are not fully explained by tradi-
tional cardiovascular risk factor. Osteoprotegerin (OPG) has been
shown as an independent predictor of mortality in CKD patients
and proposed as a potential biomarker for vascular calciﬁcation.
Methods: A total of 80 subjects (60 hemodialysis patients and 20-age
and sex matched healthy control) were studied. Vascular and valvular
calciﬁcation was measured using plain X-ray and transthoracic echo-
cardiography. Circulating OPG was measured in addition to standard
clinical biochemical analysis.
Results: Osteoprotegerin level showed signiﬁcant diﬀerence between
hemodialysis (5.4  2.8 pmol/l) and controls (0.96  0.41 pmol/l)
P < 0.001. Vascular calciﬁcation detected by X-Ray and valvular cal-
ciﬁcation by echocardiography was statistically signiﬁcant correlated
with serum OPG level in hemodialysis patients with signiﬁcant X-ray
calciﬁcation score p= 0.003 and overall valvular calciﬁcation with p
value <0.001.
Conclusion: There is strong positive relationship between osteoproteg-
erin and both vascular and valvular calciﬁcation in hemodialysis
patients. This positive correlation may open the gate for routine esti-
mation of this agent as a surrogate marker of cardiovascular calciﬁca-
tion in hemodialysis patients.
http://dx.doi.org/10.1016/j.ehj.2013.12.064
Should Jehovah’s Witness patients be listed for heart transplantation?
Elsayed Elmistekawy, Thierry G. Mesana, Marc Ruel
Division of Cardiac Surgery, University of Ottawa Heart Institute,
Ottawa, ON, Canada.
Abstract: This best evidence topic in Cardiac Surgery was written
according to a structured protocol. The question addressed was: for
[Jehovah’s Witness patients with end-stage heart failure] can these
patients undergo a [heart transplantation] without an increased rate
of mortality. Altogether, 133 papers were found using the reported
search strategy. Of those, 29 papers represented the best evidence to
answer the clinical question. Five papers focusing on patients of the
Jehovah’s Witness (JW) faith who had end-stage heart failure were
published. Successful heart transplantation was performed in a total
of seven patients without mortality, re-exploration or blood transfu-
sion. One patient had left ventricular reduction surgery twice and
another patient had bypass surgery several years after transplantation.
Other successful organ transplantations were also reported, including
lung, liver, kidney and pancreas in both adult and paediatric patients
of the JW faith, with comparable mortality and morbidity to non-
JW patients. A publication bias is likely; nevertheless, we conclude that
although there are no large studies directly focused on heart transplan-
tation in JW patients, a multidisciplinary team approach to such sur-
gery can make it technically feasible and without an increased
mortality risk in suitable candidates. Therefore, such patients may be
considered for heart transplantation under selected and favourable
circumstances.
http://dx.doi.org/10.1016/j.ehj.2013.12.065
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Background: Transcatheter PDA stenting is considered now as amo-
dality to improve the pulmonary blood ﬂow, as an alternative to sur-
gical aortopulmonary shunt in selected patients who are suitable for
the procedure.
Method: Between Jan 2005 to May 2011, 87 patients underwent PDA
stenting in PSCC after full assessment by echocardiogram and angio-
gram 41 patients (47%) patient have PA & VSD 25 of them with 2 ven-
tricles and the remaining 16 with single ventricle morphology, 22
(25%) patients have TOF, 24 patients (28%) have PA & IVS, 11
patients have Laser wire /RF perforation of the pulmonary valve same
time. Median age is 8 days, median weight is 3.2 kg, and procedure is
prograde or retrograde.
Result: Mean ventilatory support is 2 days, median hospital stay is 4
days, median saturation is 79%, median follow up is 45 mo, median
ﬂoroscopy time is 17.6 min (7.7–43 min), 6 (6.8%) of them has NEC
ﬁrst few days post stenting, 3 (3.4%) has stent migration, 4 (4.6%) lost
follow up, 2 (2.2%) deaths, compairing tomatching patients underwent
MBT , the result is better.
Conclusion: We conclude that PDA stenting is a safe and alternative
procedure surgical aortopulomnary shunt.
http://dx.doi.org/10.1016/j.ehj.2013.12.066
Smoking is a more dangerous risk factor than metabolic syndrome in
Egyptian patients with acute myocardial infarction
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The eﬀect of metabolic syndrome (MS) and other risk factors of
myocardial infarction (MI) are not consistent in all studies. Aim: To
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